Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 8—August 2007

Letter

Threat to Cefixime Treatment for Gonorrhea

Shigeaki Yokoi*, Takashi Deguchi*Comments to Author , Tomomi Ozawa*, Mitsuru Yasuda*, Shin-ichi Ito*, Yasuaki Kubota†, Masayoshi Tamaki†, and Shin-ichi Maeda†
Author affiliations: *Gifu University, Gifu, Japan; †Toyota Memorial Hospital, Toyota, Japan;

Main Article

Table

Antimicrobial drug susceptibilities of clinical isolates of Neisseria gonorrhoeae from patients with gonococcal urethritis treated unsuccessfully with a 3-day cefixime regimen*

Patient MIC (μg/mL)
Isolate PCG TET CFX CFD CDZ CTX LVF AZM SPC
1 Pre-Tx 4 2 0.5 1 0.125 0.125 16 0.25 16
Post-Tx 4 2 0.5 1 0.125 0.125 16 0.125 32
2 Pre-Tx 8 4 0.5 1 0.25 0.5 8 0.5 32
Post-Tx 8 2 0.5 1 0.125 0.25 8 0.5 16
3 Pre-Tx 4 2 1 2 0.25 0.125 16 0.25 16
Post-Tx 4 2 1 2 0.25 0.125 16 0.25 16
4 Pre-Tx 4 1 1 2 0.25 0.25 16 0.125 16
Post-Tx 4 2 1 2 0.25 0.25 16 0.25 32

*PCG, penicillin G; TET, tetracycline; CFX, cefixime; CFD, cefdinir; CDZ, cefodizime; CTX, ceftriaxone; LVF, levofloxacin; AZM, azithromycin; SPC, spectinomycin; Pre-Tx, isolate recovered before cefixime treatment; Post-Tx, isolate recovered after cefixime treatment, i.e., before ceftriaxone treatment.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO